Telehealth Market

The telehealth market is worth USD 86,420.0 million in 2025 and reaches USD 274,254.1 million by 2035, compounding at 12.24% a year. The figure is built bottom-up: roughly 1.81 billion virtual care encounters delivered globally in 2025 at a blended realised value of USD 47.75 per encounter across consultation services, remote monitoring, platform fees and specialty virtual programs, triangulated against payer claims data, platform disclosures and national health-system statistics, on a service-and-platform revenue boundary defined explicitly against loose definitions that bundle devices and adjacent software. Growth splits into two engines: encounter volume expands 9.4% a year, and revenue per encounter rises 2.6% a year as monitoring, specialty and program-based care take the mix.

What is the core judgment on telehealth?

Telehealth’s pandemic decade ends where every healthcare market eventually lives: in the reimbursement rulebook. The emergency-era explosion normalised virtual care as a permanent front door, utilisation settled far above pre-2020 baselines, and the business models that survived the shakeout, the collapse of growth-at-any-cost startups included, are the ones built on billable clinical value rather than venture subsidy. What decides the next decade is policy plumbing. In the largest market, the temporary flexibilities that let public-program patients use telehealth from home have been extended in short increments rather than made permanent, creating a recurring legislative cliff that every operator’s revenue model must price; parity rules, licensure compacts and controlled-substance prescribing boundaries do the same work in other systems. Meanwhile the demand engine has changed shape: direct-to-consumer virtual care found its killer categories in behavioral health and the weight-management wave, remote monitoring converted chronic care into recurring revenue with its own billing codes, and AI triage and documentation are rebuilding visit economics from the inside. This report models the market encounter by encounter, and the exclusive chapter maps reimbursement-cliff exposure line by line, because in this market a statute’s expiry date is a revenue forecast.

What counts as telehealth?

Telehealth is clinical care delivered remotely: synchronous video and phone consultations, asynchronous and message-based care, remote patient monitoring of physiologic data, and virtual-first specialty programs in behavioral health, chronic disease and lifestyle medicine, together with the platform and software fees that carry them. Market scope covers service revenue and platform fees at provider and vendor realised value, with connected devices, general EHR software and in-person hybrid visits outside the boundary, a definition the methodology states precisely because published figures diverge mostly on scope. The category sits within our digital health coverage.

Why is reimbursement the market’s operating system?

Because virtual care exists at the pleasure of the billing code. The pandemic proved the clinical model; what made it a market was payers agreeing to pay, and that agreement remains conditional. In the United States, public-program coverage of home-based telehealth runs on temporary extensions that Congress has renewed in short windows, so an expiry lapse instantly strands a share of visit volume, a cliff the industry has already brushed against; commercial parity laws vary by state, and controlled-substance prescribing over telehealth operates under repeatedly extended interim rules whose final shape decides whole business lines in behavioral and weight care. Other systems encode the same logic differently, permanent but fee-discounted virtual items in some national schemes, pilot-based reimbursement in others, and cross-border licensure limits everywhere. The model therefore treats policy as a demand variable: covered-population share, parity status and prescribing authority by market and year, with the base case assuming extension-with-friction rather than either cliff or permanence. The exclusive chapter publishes the exposure map behind that assumption, revenue at risk by payer, program and expiry date.

What keeps visits virtual?

The first driver is behavioral health’s structural shift: therapy and psychiatric care moved online more durably than any other specialty, supply shortages make virtual delivery a capacity solution rather than a convenience, and behavioral encounters anchor volume across every major market; the model tracks specialty mix explicitly.

The second driver is the weight-management wave: GLP-1-era demand built the largest direct-to-consumer virtual category in healthcare’s history, pairing prescribing, monitoring and subscription pharmacy, and its economics fund platform expansion into adjacent conditions; the model carries this program revenue as its own line with policy risk attached.

The third driver is remote monitoring’s billing codes: chronic-care monitoring earned dedicated reimbursement, converting devices-plus-oversight into recurring monthly revenue per patient, the fastest-compounding stream in the mix.

The fourth is health-system capacity economics: clinician shortages and access gaps make virtual triage, follow-up and rural specialty coverage a cost answer for systems themselves, embedding telehealth in operations independent of consumer preference.

What pulls care back in person?

Three restraints are modelled. Policy cliffs lead, as the previous section details: the base case prices extension friction, and the downside applies a lapse. Clinical-scope ceilings are second: examination, procedures and diagnostics bound what virtual care can bill, hybrid models return a share of encounters to facilities, and utilisation review pushes back where virtual visits duplicate rather than replace; the model caps substitution honestly by specialty. Third is unit-economics pressure: visit prices deflate under competition and payer scrutiny while clinician costs rise, squeezing pure-consultation models, which is exactly why the mix shifts toward monitoring and programs, and why AI-driven documentation and triage matter to margins; the pricing chapter quantifies both.

Which services bill the revenue?

Teleconsultation services lead with 52% of 2025 revenue, USD 44,938.4 million, the visit engine across primary, urgent and specialty care. Remote patient monitoring holds 21%, USD 18,148.2 million, and compounds fastest on chronic-care codes. Platforms and software take 17%, USD 14,691.4 million, the fees carrying health-system and employer deployments, and behavioral and specialty virtual programs contribute 10%, USD 8,642.0 million, the direct-to-consumer frontier led by weight and mental health. Each stream is modelled from encounters and realised values, with revenue tables through 2035 and the monitoring crossover year stated.

Where is virtual care scaling?

North America leads with 42% of 2025 revenue, USD 36,296.4 million, on utilisation depth and the richest reimbursement architecture, growing 11.2% a year. Asia Pacific holds 26%, USD 22,469.2 million, and compounds fastest at 13.9% as Chinese internet-hospital volume, Indian teleconsultation platforms and regional public programs scale access. Europe follows at 22%, USD 19,012.4 million, at 11.7% across national-scheme integrations. Latin America contributes USD 4,321.0 million at 13.0%, the Middle East USD 2,765.4 million at 13.6% on digital-health programs, and Africa USD 1,555.6 million at 12.5%, where virtual delivery leapfrogs facility gaps. Six regional models sum to the global figure, with country tables in the Excel model.

Who runs the platforms?

Teladoc Health anchors the category as the scale reference across employer, payer and consumer channels, and Amwell carries the health-system platform franchise through its rebuilt technology stack. Included Health represents the employer-navigation model pairing virtual care with advocacy, Hims & Hers leads the direct-to-consumer tier that the weight wave supercharged, and Doctolib anchors Europe’s practice-platform model where booking infrastructure became the virtual-care rail. Around them sit national internet-hospital giants in Asia, payer-owned virtual clinics, and the AI-native entrants attacking documentation and triage economics. The competitive chapter profiles each model’s encounter economics, payer mix, policy exposure and AI leverage, because in this market the business model is the moat.

What does a virtual visit cost?

Blended realised value averages USD 47.75 per encounter in 2025 across a wide ladder: high-volume Asian consultations in the single dollars, subscription and message-based care spreading fees across contacts, insured video visits from roughly USD 40 to 90, monitoring programs billing monthly per patient, and specialty programs bundling prescribing and pharmacy at premium monthly rates. The 2.6% annual mix growth comes from monitoring and programs, not visit-price inflation, which competition holds flat to negative. The pricing chapter publishes realised bands by stream and market, reimbursement rates and parity structures, subscription economics, and the AI-era cost-per-encounter curves that decide margins.

How do the scenarios connect 2035?

The base case carries 9.4% encounter growth and 2.6% mix for a 12.24% revenue CAGR and USD 274,254.1 million in 2035. The cliff scenario, applying a flexibility lapse in the largest market plus prescribing tightening, trims the legs to 6.8% and 1.6%, landing near USD 195,000 million. The permanence scenario, with flexibilities made permanent and monitoring codes expanding, lifts the legs to 10.8% and 3.2%, carrying the market past USD 320,000 million. Each 1-point change in encounter growth moves the 2035 figure by roughly USD 24,000 million. Published telehealth forecasts span roughly 10% to 24% CAGRs on wildly different boundaries; ours sits deliberately below the loose end on a service-revenue definition, and the report states exactly which scope choices separate the estimates.

Which rules govern virtual practice?

Four regulatory layers define the market. Reimbursement first, as the operating system above: coverage, parity and program rules by payer and market, with the extension calendar tracked to dates. Licensure second: clinicians practice where the patient sits, interstate and cross-border compacts widen reach unevenly, and platform models are built around these maps. Prescribing third: controlled-substance rules over telehealth, under repeatedly extended interim frameworks in the United States, bound behavioral and weight-care models, and their final form is the single most consequential open rulemaking in the category. Privacy and platform regulation fourth: health-data rules, advertising-tracker enforcement and, for AI-assisted care, the emerging clinical-AI oversight that documentation and triage tools are entering. The regulatory chapter maps all four by market with dates, because in telehealth the compliance calendar is the strategic calendar.

Why did behavioral health become telehealth’s anchor?

Behavioral health became telehealth’s anchor because therapy and psychiatry translate to video better than almost any other specialty and because demand far exceeds the supply of clinicians. A therapy session needs conversation, not examination, so the clinical loss from remote delivery is minimal, and patients value privacy, the absence of a waiting room and the ability to book evening appointments. Shortages of psychiatrists and therapists, particularly outside large cities, mean virtual delivery expands effective capacity rather than merely relocating it, and employers and insurers have expanded behavioral benefits because untreated mental illness drives absence and medical costs. The result is that behavioral health accounts for a disproportionate share of virtual visits in mature markets, far above its share of in-person care, and it has the highest repeat-visit rate, which makes it commercially attractive. The complications are prescribing rules for controlled medicines used in psychiatry, which depend on the interim frameworks discussed above, and quality concerns about high-volume, low-contact models. The model treats behavioral health as the largest and most durable component of teleconsultation volume.

How did weight-management platforms change the industry?

Weight-management platforms changed the industry by proving that consumers will pay directly for virtual care when the outcome matters enough to them. The arrival of highly effective obesity medicines created demand that primary care could not absorb, and virtual providers built subscription services combining clinician consultations, prescribing, laboratory work, coaching and, in some cases, pharmacy supply. Revenue per patient far exceeded that of an ordinary video visit, and the category became the fastest-growing part of direct-to-consumer healthcare. It also attracted scrutiny: regulators examined advertising and prescribing practices, questions arose about compounded versions of branded medicines when supply was short, and payers weighed whether to cover treatment at scale. The commercial risk is concentration, because a few medicines and their supply and pricing decisions drive the whole category. For this market, weight management is counted within behavioral and specialty programmes, it lifts revenue per encounter materially, and the model treats it as high-growth but policy-sensitive.

What does licensure do to where care can be delivered?

Licensure determines where a clinician may practise, and it shapes every virtual care business model. In most systems a clinician must be licensed in the jurisdiction where the patient is physically located, not where the clinician sits, so a national virtual service must either employ clinicians licensed in every state or country it serves or restrict coverage. In the United States, interstate compacts for physicians, nurses, psychologists and counsellors have reduced friction by streamlining multi-state licensure, but participation varies by state and profession. In Europe, cross-border care rules allow some movement but national registration still governs practice, and in emerging markets rules are often unsettled. The practical effect is that virtual providers invest heavily in licensing operations, that clinician supply in high-demand specialties is allocated across states rather than expanded, and that rural access depends on the compacts. The model carries licensure reach as a constraint on how quickly platforms can scale.

How do other health systems deliver virtual care?

Outside the United States, virtual care is usually embedded in public systems rather than sold separately. In the United Kingdom, general practices offer telephone and video consultations and online triage as part of routine access, with funding through existing contracts rather than separate fees. Nordic countries and the Netherlands integrate video visits and remote monitoring into primary and chronic care. China’s internet hospitals, licensed extensions of physical hospitals, deliver very large volumes of consultations and prescriptions with insurance coverage in many provinces, and India’s public telemedicine service and private platforms serve areas with few doctors. These models generate lower revenue per encounter than American virtual care but far greater volume, which is why Asia Pacific contributes a large share of global encounters while North America contributes the largest share of revenue. The model prices each market separately rather than applying American economics globally.

Douglas Exclusive: the reimbursement-cliff exposure map

Every operator and investor in this market carries policy risk they rarely quantify, so this report maintains the map. The exclusive chapter tracks revenue exposure by policy line: flexibility provisions with expiry dates and the encounter volume riding on each, parity statutes by state and market, prescribing-rule scenarios for behavioral and weight programs, and national-scheme fee reviews with their calendars. It scores the public operators and major private models on cliff exposure and diversification, and stress-tests the base case against each lapse. Licence holders receive it as a maintained tab in the Excel model, updated each edition as legislation moves.

Methodology and receipts

The model is built bottom-up from encounters: visit, monitoring and program volumes by market from claims, platform and health-system data, priced at realised values by stream, with the service-and-platform boundary stated precisely and policy variables, coverage, parity, prescribing, carried explicitly by market and year. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The full method follows the published Douglas Insights methodology. The next scheduled review of this study is September 2027, with material changes published in the edition change log.